World Heart Corp has received a $10-million repayable loan from Technology Partnerships Canada (TPC) to conduct clinical trials of its first generation HeartSaver ventricular assist device (VAD). TPC has also indicated it will consider funding the next two generations of the fully implantable heart assist device. Ottawa-based World Heart has been developing the product for the past several years, targeting patients awaiting heart transplants and those less-critical individuals requiring indeterminate care. The medical device is powered and monitored wirelessly, providing pulse and enhanced blood flow….
Other stories mentioning these organizations, people and topics
| Organizations: | Technology Partnerships Canada and World Heart Corp |
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 1 free article remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.